{ "instance": { "utrs-20210930.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 285, "dts": { "calculationLink": { "local": [ "utrs-20210930_cal.xml" ] }, "definitionLink": { "local": [ "utrs-20210930_def.xml" ] }, "inline": { "local": [ "utrs-20210930.htm" ] }, "labelLink": { "local": [ "utrs-20210930_lab.xml" ] }, "presentationLink": { "local": [ "utrs-20210930_pre.xml" ] }, "schema": { "local": [ "utrs-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 617, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 3, "http://xbrl.sec.gov/dei/2021": 4, "total": 7 }, "keyCustom": 86, "keyStandard": 360, "memberCustom": 36, "memberStandard": 36, "nsprefix": "utrs", "nsuri": "http://minervasurgical.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Revenue", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value Measurements", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Balance Sheet Components", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Business Combination", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombination", "shortName": "Business Combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Debt", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Commitments and Contingencies", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Income Taxes", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "utrs:RedeemableConvertiblePreferredStockWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Redeemable Convertible Preferred Stock Warrants", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrants", "shortName": "Redeemable Convertible Preferred Stock Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "utrs:RedeemableConvertiblePreferredStockWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Stockholders' Deficit", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficit", "shortName": "Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Net Loss Per Share Attributable To Common Stockholders", "role": "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders2", "shortName": "Net Loss Per Share Attributable To Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Balance Sheets", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Employee Benefit Plan", "role": "http://minervasurgical.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlan", "shortName": "Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Related Party Transactions", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Subsequent Events", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Revenue (Tables)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Fair Value Measurements (Tables)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Balance Sheet Components (Tables)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Business Combination (Tables)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationTables", "shortName": "Business Combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Debt (Tables)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Balance Sheets (Parenthetical)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "utrs:RedeemableConvertiblePreferredStockWarrantsTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "utrs:SummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Redeemable Convertible Preferred Stock Warrants (Table)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsTable", "shortName": "Redeemable Convertible Preferred Stock Warrants (Table)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "utrs:RedeemableConvertiblePreferredStockWarrantsTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "utrs:SummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "utrs:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Stockholders' Deficit (Tables)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitTables", "shortName": "Stockholders' Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "utrs:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Net Loss Per Share Attributable To Common Stockholders (Tables)", "role": "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable To Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Formation and Business of the Company - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "shortName": "Formation and Business of the Company - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_94bcd58b-004a-4363-a6e6-b8629ab5366a", "decimals": "INF", "lang": null, "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "INF", "first": true, "lang": null, "name": "utrs:NumberOfCustomerAccountedForAccountsReceivableOrRevenue", "reportCount": 1, "unique": true, "unitRef": "U_Customer", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Summary of significant accounting policies - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of significant accounting policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "INF", "first": true, "lang": null, "name": "utrs:NumberOfCustomerAccountedForAccountsReceivableOrRevenue", "reportCount": 1, "unique": true, "unitRef": "U_Customer", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "2", "first": true, "lang": null, "name": "utrs:PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Revenue - Schedule of Disaggregation of Revenue (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails", "shortName": "Revenue - Schedule of Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "2", "first": true, "lang": null, "name": "utrs:PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "utrs:PercentageOfRevenueSubjectToPointInTimeRecognition", "utrs:PercentageOfRevenueSubjectToPointInTimeRecognition", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "3", "first": true, "lang": null, "name": "utrs:PercentageOfRevenueSubjectToPointInTimeRecognition", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Revenue - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails", "shortName": "Revenue - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "utrs:PercentageOfRevenueSubjectToPointInTimeRecognition", "utrs:PercentageOfRevenueSubjectToPointInTimeRecognition", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "3", "first": true, "lang": null, "name": "utrs:PercentageOfRevenueSubjectToPointInTimeRecognition", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Revenue - Schedule of Contract Balance (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfContractBalanceDetails", "shortName": "Revenue - Schedule of Contract Balance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerReceivableAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Fair Value Measurement - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails", "shortName": "Fair Value Measurement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Statements of Operations", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations", "shortName": "Condensed Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "utrs:FairValueDerivativeLiabilitiesExpectedExitDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Fair Value Measurements - Schedule Of Convertible Notes Derivative Liabilities Determined Using Assumptions (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfConvertibleNotesDerivativeLiabilitiesDeterminedUsingAssumptionsDetails", "shortName": "Fair Value Measurements - Schedule Of Convertible Notes Derivative Liabilities Determined Using Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "utrs:FairValueDerivativeLiabilitiesExpectedExitDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_5672127f-28b6-4d01-96a6-fe4ef13b98c8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair Value - Summary of Redeemable Convertible Preferred Stock Warrant Liability (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails", "shortName": "Fair Value - Summary of Redeemable Convertible Preferred Stock Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_949772d9-d2bb-4540-9c4d-b3f0dff7aabf", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetails", "shortName": "Balance Sheet Components - Schedule of Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetails", "shortName": "Balance Sheet Components - Schedule of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "utrs:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "utrs:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Balance Sheet Components - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "shortName": "Balance Sheet Components - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedTrademarksGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Balance Sheet Components - Schedule of Intangible Asset, Net (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails", "shortName": "Balance Sheet Components - Schedule of Intangible Asset, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedTrademarksGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Balance Sheet Components - Schedule of Future Amortization Expense of Intangible Assets (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails", "shortName": "Balance Sheet Components - Schedule of Future Amortization Expense of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "utrs:ScheduleOfAccruedCompensationTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedVacationCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Balance Sheet Components - Schedule of Accrued Compensation (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails", "shortName": "Balance Sheet Components - Schedule of Accrued Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "utrs:ScheduleOfAccruedCompensationTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedVacationCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Statements of Operations (Parenthetical)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsParenthetical", "shortName": "Condensed Statements of Operations (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestExpenseRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "utrs:AccruedLitigation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Balance Sheet Components - Schedule of Accrued Liabilities (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails", "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "utrs:AccruedLitigation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_86b9d0fd-d362-4dc8-922a-db288ebb0354", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Business Combination - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "shortName": "Business Combination - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_86b9d0fd-d362-4dc8-922a-db288ebb0354", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_078aec82-918c-4b84-98e4-aaf5f9c98f90", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Business Combination - Schedule of Purchase Price of Acquired Assets and Liabilities (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails", "shortName": "Business Combination - Schedule of Purchase Price of Acquired Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_078aec82-918c-4b84-98e4-aaf5f9c98f90", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Debt - Ares Term Loan - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "shortName": "Debt - Ares Term Loan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8726f8c6-c7b0-4fc0-a99a-b047becb463d", "decimals": "-5", "lang": null, "name": "utrs:DebtInstrumentAdvancedAtClosingOfAgreementTrancheA", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_63bec765-4c26-4298-b6f9-349d4eb3a0c3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Debt - Ares Term Loan - Schedule of Debt (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails", "shortName": "Debt - Ares Term Loan - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_63bec765-4c26-4298-b6f9-349d4eb3a0c3", "decimals": "-3", "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Debt - Paycheck Protection Program - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails", "shortName": "Debt - Paycheck Protection Program - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_ef88a10f-a6dc-45ba-adb4-bdc99c00fa1b", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Debt - Convertible Notes - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "shortName": "Debt - Convertible Notes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-5", "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "utrs:ConvertibleNotesPayables", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Debt - Convertible Notes - Schedule of Convertible Note (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails", "shortName": "Debt - Convertible Notes - Schedule of Convertible Note (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_615339b3-4e02-4e95-9771-4c84e0d01ca6", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_f02f15a5-a58e-4617-b6eb-5fa1f0e7d5d7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Debt - Schedule of Contractual Maturities of Financing Obligations (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails", "shortName": "Debt - Schedule of Contractual Maturities of Financing Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_f02f15a5-a58e-4617-b6eb-5fa1f0e7d5d7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails", "shortName": "Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8a3cecbf-8c1c-4a50-b2c4-73d786a8966e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit", "shortName": "Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_f7bcc7ef-9648-4e52-98cc-03d7255453e4", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "utrs:SummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsTableTextBlock", "div", "utrs:RedeemableConvertiblePreferredStockWarrantsTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_d7ecf99b-342f-4b51-8947-b2ac069406ee", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Redeemable Convertible Preferred Stock Warrants - Summary Of Outstanding Redeemable Convertible Preferred Stock Warrants (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails", "shortName": "Redeemable Convertible Preferred Stock Warrants - Summary Of Outstanding Redeemable Convertible Preferred Stock Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "utrs:SummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsTableTextBlock", "div", "utrs:RedeemableConvertiblePreferredStockWarrantsTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_d7ecf99b-342f-4b51-8947-b2ac069406ee", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Redeemable Convertible Preferred Stock Warrants - Schedule of Share based Payment Award, Stock Options, Valuation Assumptions (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "shortName": "Redeemable Convertible Preferred Stock Warrants - Schedule of Share based Payment Award, Stock Options, Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "utrs:RedeemableConvertiblePreferredStockWarrantsTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_93e6ecbc-a158-4a98-9350-92ac58407c53", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Stockholders' Deficit - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "shortName": "Stockholders' Deficit - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "utrs:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "0", "first": true, "lang": null, "name": "utrs:WarrantsToPurchaseRedeemableConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Stockholders' Deficit - Schedule of Shares Reserved for Future Issuance (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails", "shortName": "Stockholders' Deficit - Schedule of Shares Reserved for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "utrs:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "0", "first": true, "lang": null, "name": "utrs:WarrantsToPurchaseRedeemableConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "utrs:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "INF", "first": true, "lang": null, "name": "utrs:ConversionsOfConvertibleNotesToPreferredStock", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Stockholders' Deficit - Schedule of Shares Reserved for Future Issuance (Parenthetical) (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceParentheticalDetails", "shortName": "Stockholders' Deficit - Schedule of Shares Reserved for Future Issuance (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "utrs:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "INF", "first": true, "lang": null, "name": "utrs:ConversionsOfConvertibleNotesToPreferredStock", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_90cd1830-ddad-463b-8af4-6b47aa75aee6", "decimals": "INF", "first": true, "lang": null, "name": "utrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Stockholders' Deficit - Schedule of Stock Option Activity (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails", "shortName": "Stockholders' Deficit - Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "INF", "lang": null, "name": "utrs:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Stockholders' Deficit -Summary of Stock-Based Compensation Expense (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails", "shortName": "Stockholders' Deficit -Summary of Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Stockholders' Deficit -Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "shortName": "Stockholders' Deficit -Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Statements of Cash Flows", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_0fd216ae-aa71-4564-a5af-822f07b50a4c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_0fd216ae-aa71-4564-a5af-822f07b50a4c", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "us-gaap:DebtConversionConvertedInstrumentAmount1", "us-gaap:DebtConversionConvertedInstrumentAmount1", "span", "p", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_02b63ad9-874f-4a48-85f1-37bd1d7c8239", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding (Parenthetical) (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom1", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_4624841c-cb99-48df-a681-ab2e40ba4594", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_4624841c-cb99-48df-a681-ab2e40ba4594", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_54dddc96-b04a-402f-ba74-3546def6cd75", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8d49c8c5-d394-4106-bc58-3a42d8ce63c1", "decimals": "-5", "lang": null, "name": "utrs:DelayedCashPurchaseConsideration", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Formation and Business of the Company", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompany", "shortName": "Formation and Business of the Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "role": "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "utrs-20210930.htm", "contextRef": "C_8f65ef7a-b744-48c3-a213-d41fe807414c", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 73, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r591" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r66", "r68", "r119", "r120", "r248", "r295" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Board of Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r247", "r294", "r358", "r361", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r573", "r575", "r588", "r589" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r247", "r294", "r358", "r361", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r573", "r575", "r588", "r589" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r177", "r333", "r336", "r522", "r572", "r574" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r177", "r333", "r336", "r522", "r572", "r574" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r247", "r294", "r347", "r358", "r361", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r573", "r575", "r588", "r589" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r247", "r294", "r347", "r358", "r361", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r573", "r575", "r588", "r589" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r67", "r68", "r119", "r120", "r248", "r295" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r131", "r135", "r359" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r131", "r135", "r217", "r359", "r507" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r180", "r498" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r43", "r504" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r26", "r181", "r182" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrentAndNoncurrent": { "auth_ref": [ "r546", "r566" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails": { "order": 1.0, "parentTag": "utrs_AccruedCompensation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.", "label": "Accrued Bonuses Current And Noncurrent", "terseLabel": "Accrued bonuses" } } }, "localname": "AccruedBonusesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued liabilities", "totalLabel": "Accrued Liabilities, Current, Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r546", "r566" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities Current And Noncurrent", "terseLabel": "Expenses incurred in connection with offering not yet paid", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "auth_ref": [ "r546", "r566" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.", "label": "Accrued Professional Fees Current And Noncurrent", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedVacationCurrentAndNoncurrent": { "auth_ref": [ "r344", "r546", "r566" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails": { "order": 0.0, "parentTag": "utrs_AccruedCompensation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees.", "label": "Accrued Vacation Current And Noncurrent", "terseLabel": "Accrued vacation" } } }, "localname": "AccruedVacationCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r209" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: accumulated depreciation and amortization", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r29", "r72", "r73", "r74", "r561", "r580", "r581" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive income", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r71", "r74", "r77", "r78", "r79", "r123", "r124", "r125", "r447", "r576", "r577", "r600" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r27", "r391", "r504" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid In Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r123", "r124", "r125", "r388", "r389", "r390", "r456" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r363", "r364", "r394", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r364", "r384", "r393" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r88", "r101", "r267", "r483" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization Of Debt Discount Premium", "terseLabel": "Amortization of debt premium and discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r101", "r267", "r280", "r281", "r485" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization Of Financing Costs And Discounts", "terseLabel": "Amortization of debt discount and debt issuance costs", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r101", "r195", "r202" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization Of Intangible Assets", "terseLabel": "Amortization expense on intangible assets", "totalLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r114", "r166", "r169", "r175", "r186", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r443", "r448", "r473", "r502", "r504", "r540", "r558" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r10", "r62", "r114", "r186", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r443", "r448", "r473", "r502", "r504" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r458" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r452", "r454" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r357", "r360" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r357", "r360", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r415", "r416" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Business acquisition, pro forma net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r415", "r416" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Business acquisition, pro forma revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquiredReceivablesDescription": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "This element represents a narrative description of the nature of receivables acquired in a business combination (as defined) including the nature of the receivables (such as loans, capital leases), the fair value of the acquired receivables, the gross contractual amount to be collected, and the amount estimated to be doubtful of collection, if any.", "label": "Business Combination Acquired Receivables Description", "terseLabel": "Business combination description" } } }, "localname": "BusinessCombinationAcquiredReceivablesDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount": { "auth_ref": [ "r426", "r427", "r428", "r430", "r431", "r438" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity.", "label": "Business Combination Bargain Purchase Gain Recognized Amount", "negatedLabel": "Bargain purchase gain" } } }, "localname": "BusinessCombinationBargainPurchaseGainRecognizedAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r432", "r433", "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Purchase price", "totalLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination Consideration Transferred [Abstract]", "terseLabel": "Net assets acquired:" } } }, "localname": "BusinessCombinationConsiderationTransferredAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r100", "r439" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1", "terseLabel": "Change in fair value of contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r429", "r434", "r437" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination Contingent Consideration Liability", "terseLabel": "Contingent consideration liability", "totalLabel": "Business Combination, Contingent Consideration, Liability, Total" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r429", "r435" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination Contingent Consideration Liability Current", "terseLabel": "Contingent consideration liability, current" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r429", "r435" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination Contingent Consideration Liability Noncurrent", "terseLabel": "Contingent consideration liability, net of current portion" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination Description [Abstract]" } } }, "localname": "BusinessCombinationDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r421" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred tax liability", "terseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r421" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets, other than goodwill", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r419", "r421" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r419", "r421" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment", "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r122", "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Formation and Business of the Company" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompany" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r39", "r504", "r582", "r583" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetails": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash, Ending Balance", "periodStartLabel": "Cash, Beginning Balance", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r39", "r103" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents At Carrying Value [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r97", "r103", "r108" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period", "terseLabel": "Cash, cash equivalents and restricted cash in balance sheets", "totalLabel": "Cash, cash equivalents and restricted cash in balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r97", "r474" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r39" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Equivalents At Carrying Value [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental Disclosure of Non-cash Items:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r111", "r114", "r136", "r137", "r138", "r140", "r142", "r148", "r149", "r150", "r186", "r230", "r235", "r236", "r237", "r241", "r242", "r291", "r292", "r297", "r301", "r473", "r596" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsTable", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsTable", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Outstanding", "terseLabel": "Shares" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r216", "r547", "r565" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r213", "r214", "r215", "r225", "r587" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock available for future grants" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r123", "r124", "r456" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares, Issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25", "r504" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.001 par value, 144,406,928 shares authorized as of September 30, 2021 and December 31, 2020; 3,149,777 and 1,192,299 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r345", "r346", "r362", "r396" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation And Employee Benefit Plans [Text Block]", "terseLabel": "Employee Benefit Plan" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureEmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r153", "r556" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": { "auth_ref": [ "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.", "label": "Contingent Consideration Classified As Equity Fair Value Disclosure", "terseLabel": "Fair value of contingent consideration" } } }, "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract With Customer Asset And Liability [Abstract]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract With Customer Asset And Liability Table [Text Block]", "terseLabel": "Schedule of Contract Balance" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r321", "r322", "r334" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Contract liability\u2014current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfContractBalanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerReceivableAllowanceForCreditLoss": { "auth_ref": [ "r188", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional.", "label": "Contract With Customer Receivable Allowance For Credit Loss", "terseLabel": "Accounts receivable" } } }, "localname": "ContractWithCustomerReceivableAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfContractBalanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r243", "r244", "r245", "r247", "r257", "r258", "r259", "r263", "r264", "r265", "r266", "r267", "r278", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Note", "verboseLabel": "Convertible Promissory Notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible Notes" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt Table [Text Block]", "terseLabel": "Schedule of Convertible Note" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r291", "r292", "r297" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r23", "r24", "r304", "r310", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Redeemable convertible preferred stock converted" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockSharesReservedForFutureIssuance": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of nonredeemable convertible preferred shares reserved for future issuance.", "label": "Convertible Preferred Stock Shares Reserved For Future Issuance", "terseLabel": "Convertible preferred stock reserved for future issuance" } } }, "localname": "ConvertiblePreferredStockSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r85", "r522" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost Of Goods And Services Sold", "terseLabel": "Cost of goods sold", "totalLabel": "Cost of Goods and Services Sold, Total" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of Goods Sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r105", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Conversion of convertible notes to preferred stock", "verboseLabel": "Aggregate outstanding principal and accrued interest of convertible promissory notes" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom1", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r105", "r107" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Conversion of preferred stock" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r110", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r261", "r268", "r269", "r271", "r284" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r20", "r21", "r113", "r121", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r257", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r278", "r279", "r280", "r281", "r487", "r541", "r542", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r21", "r272", "r542", "r557" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails": { "order": 0.0, "parentTag": "utrs_ConvertibleNotesPayables", "weight": 1.0 }, "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount", "terseLabel": "Debt financing", "totalLabel": "Total", "verboseLabel": "Principal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r246", "r275" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r51", "r310", "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Debt Instrument, Convertible, Terms of Conversion Feature", "terseLabel": "Debt instrument, convertible, terms of conversion feature" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness", "terseLabel": "Debt instrument forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r244", "r278", "r279", "r484", "r487", "r488" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Amount borrowed" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r259", "r278", "r279", "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Estimated fair value of aggregate outstanding derivative instrument", "totalLabel": "Debt Instrument, Fair Value Disclosure, Total" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r48", "r276", "r484", "r487" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument Interest Rate Effective Percentage", "terseLabel": "Debt instrument effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r48", "r245" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument Interest Rate Terms", "terseLabel": "Debt instrument, interest rate terms" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r49", "r247", "r462" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52", "r113", "r121", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r257", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r278", "r279", "r280", "r281", "r487" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r50", "r554" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "terseLabel": "Debt instrument payment terms" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r52", "r554" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument Periodic Payment", "terseLabel": "Debt instrument, periodic payment", "totalLabel": "Debt Instrument, Periodic Payment, Total" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r113", "r121", "r244", "r245", "r246", "r247", "r248", "r249", "r251", "r257", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r278", "r279", "r280", "r281", "r310", "r314", "r315", "r316", "r483", "r484", "r487", "r488", "r555" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r257", "r273", "r278", "r279", "r485" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 }, "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net", "negatedLabel": "Net of unamortized debt premium (discounts) and issuance costs", "negatedTerseLabel": "Less: Debt issuance cost and debt discount", "terseLabel": "Less: net of unamortized debt premium (discounts) and issuance costs", "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r257", "r483", "r484", "r485", "r486", "r488" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails": { "order": 2.0, "parentTag": "utrs_ConvertibleNotesPayables", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Debt premium (discount)", "terseLabel": "Less: debt discount", "totalLabel": "Debt Instrument, Unamortized Discount (Premium), Net, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees And Debt Issuance Costs", "terseLabel": "Interest Expense related to debt discount , debt issuance costs and exit fees" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r42", "r257", "r485" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails": { "order": 1.0, "parentTag": "utrs_ConvertibleNotesPayables", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Less: debt issuance costs", "terseLabel": "Less: debt issuance costs", "totalLabel": "Debt Issuance Costs, Net, Total" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r115", "r402", "r407", "r408", "r409" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes", "totalLabel": "Deferred Income Tax Expense (Benefit), Total" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r61", "r193" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs other than underwriting discounts and commissions", "verboseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue Revenue Recognized1", "terseLabel": "revenue" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r101", "r207" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r101", "r164" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization expense on property and equipment", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueHedgeIncludedInEffectivenessGainLoss": { "auth_ref": [ "r455" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on derivative instrument designated and qualifying as fair value hedge included in assessment of hedge effectiveness, recognized in earnings.", "label": "Derivative Fair Value Hedge Included In Effectiveness Gain Loss", "negatedLabel": "Change in fair value of derivative liabilities" } } }, "localname": "DerivativeFairValueHedgeIncludedInEffectivenessGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r63", "r68", "r69", "r453", "r518" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Fair Value Of Derivative Liability", "terseLabel": "Derivative liability, fair value", "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Derivative Liabilities" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r64", "r65", "r68", "r470" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 0.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liabilities", "terseLabel": "Derivative liabilities", "totalLabel": "Derivative Liability, Total" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r64" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liabilities Noncurrent", "terseLabel": "Derivative liabilities (includes $14.4 million at September 30, 2021 and $23.6 million at December 31, 2020, respectively, attributable to related parties)" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability, Measurement Input", "terseLabel": "Discount rate" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfConvertibleNotesDerivativeLiabilitiesDeterminedUsingAssumptionsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology Rights" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r333", "r336", "r337", "r338", "r339", "r340", "r341", "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block Supplement [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r118", "r233", "r235", "r236", "r240", "r241", "r242", "r496", "r544", "r568" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due From Related Parties", "terseLabel": "Related party transaction amount owned", "totalLabel": "Due from Related Parties, Total" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToAffiliateCurrent": { "auth_ref": [ "r18", "r118", "r496", "r584" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due To Affiliate Current", "terseLabel": "Manufacturing transfer agreement" } } }, "localname": "DueToAffiliateCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r118", "r233", "r235", "r236", "r240", "r241", "r242", "r496", "r545", "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Related party transaction amount owned", "totalLabel": "Due to Related Parties, Total" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income (loss) per share attributable to common stockholders:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share attributable to common stockholders, basic and diluted", "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net loss per share attributable to common stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r143", "r144", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders2" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits And Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued compensation", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Unrecognized stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Compensation expense not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Options to Purchase Common Stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r77", "r78", "r79", "r123", "r124", "r125", "r127", "r132", "r134", "r147", "r187", "r309", "r317", "r388", "r389", "r390", "r403", "r404", "r456", "r475", "r476", "r477", "r478", "r479", "r480", "r576", "r577", "r578", "r600" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage", "terseLabel": "Related party transaction ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r458", "r459", "r460", "r466" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfConvertibleNotesDerivativeLiabilitiesDeterminedUsingAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfConvertibleNotesDerivativeLiabilitiesDeterminedUsingAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule Of Convertible Notes Derivative Liabilities Determined Using Assumptions" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r458", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value By Balance Sheet Grouping [Table]", "terseLabel": "Fair Value By Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r259", "r278", "r279", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r356", "r459", "r509", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r465", "r466" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r259", "r348", "r349", "r354", "r356", "r459", "r509" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r259", "r278", "r279", "r348", "r349", "r354", "r356", "r459", "r510" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r259", "r278", "r279", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r356", "r459", "r511" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]" } } }, "localname": "FairValueInputsQuantitativeInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r463", "r466" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Schedule of Change in Fair Value of the Redeemable Convertible Preferred Stock Warrant Liability, Derivative Liabilities and Contingent Consideration Liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement Inputs Disclosure [Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings", "terseLabel": "Recognition" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "terseLabel": "Change in fair value", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r463" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value", "periodEndLabel": "Ending fair value", "periodStartLabel": "Beginning fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r259", "r278", "r279", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r356", "r509", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r467", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableImpairedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable Impaired [Line Items]", "terseLabel": "Financing Receivable Impaired [Line Items]" } } }, "localname": "FinancingReceivableImpairedLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedCustomerRelationshipsGross": { "auth_ref": [ "r201" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date to an asset acquired in a business combination representing a favorable existing relationship with customers having a finite beneficial life.", "label": "Finite Lived Customer Relationships Gross", "terseLabel": "Customer relationships" } } }, "localname": "FiniteLivedCustomerRelationshipsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite Lived Intangible Asset Useful Life", "terseLabel": "Intangible assets, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r201" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Accumulated Amortization", "negatedLabel": "Less: accumulated depreciation and amortization", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r203" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "utrs_FiniteLivedFutureAmortizationOfIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 0.0, "parentTag": "utrs_FiniteLivedFutureAmortizationOfIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year", "terseLabel": "2021 (remaining three months)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r203" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 4.0, "parentTag": "utrs_FiniteLivedFutureAmortizationOfIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r203" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 3.0, "parentTag": "utrs_FiniteLivedFutureAmortizationOfIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r203" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "utrs_FiniteLivedFutureAmortizationOfIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r196", "r198", "r201", "r205", "r523", "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r201", "r524" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails": { "order": 0.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross", "totalLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r196", "r200" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r201", "r523" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Net", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "terseLabel": "Intangible asset, net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedTrademarksGross": { "auth_ref": [ "r201" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a specified period of time.", "label": "Finite Lived Trademarks Gross", "terseLabel": "Trademarks" } } }, "localname": "FiniteLivedTrademarksGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r101", "r282", "r283" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (loss) on extinguishment of debt", "negatedLabel": "Loss on extinguishment of convertible notes", "terseLabel": "Loss on extinguishment of convertible notes", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "verboseLabel": "Gain on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r84", "r114", "r166", "r168", "r171", "r174", "r176", "r186", "r230", "r231", "r232", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r473" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]", "terseLabel": "Numerator" } } }, "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r81", "r166", "r168", "r171", "r174", "r176", "r537", "r548", "r552", "r570" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Net Income (Loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r116", "r399", "r400", "r401", "r405", "r410", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r117", "r133", "r134", "r165", "r398", "r406", "r411", "r571" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax benefit", "terseLabel": "Income tax (benefit) provision", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r100" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r100" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r100" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase Decrease In Accrued Liabilities", "terseLabel": "Accrued liabilities", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r100" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory", "terseLabel": "Inventory", "totalLabel": "Increase (Decrease) in Inventories, Total" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Net changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r100" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInWorkersCompensationLiabilities": { "auth_ref": [ "r100" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due for insurance (or actual expenses) to cover the medical expenses and lost income for employees that are injured during the course of doing work-related activities.", "label": "Increase Decrease In Workers Compensation Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInWorkersCompensationLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r197", "r204" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Indefinite-lived Intangible Assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r197", "r204" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r194", "r199" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible asset, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r80", "r163", "r482", "r485", "r551" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense (includes $1.3 million to related parties in three months ended September 30, 2021 and 2020 and $4.2 million and $3.2 million to related parties in nine months ended September 30, 2021 and 2020, respectively)", "terseLabel": "Interest expense", "totalLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r88", "r265", "r277", "r280", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense Debt", "terseLabel": "Interest expense on debt", "totalLabel": "Interest Expense, Debt, Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseLongTermDebt": { "auth_ref": [ "r550", "r596", "r597" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of interest paid or due on all long-term debt.", "label": "Interest Expense Long Term Debt", "terseLabel": "Non-cash interest expense from long-term debt and convertible notes", "totalLabel": "Interest Expense, Long-term Debt, Total" } } }, "localname": "InterestExpenseLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense Related Party", "terseLabel": "Interest Expense, Related Party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperationsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r95", "r98", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r33", "r189" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory Finished Goods Net Of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r60", "r504" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r87", "r162" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income", "totalLabel": "Investment Income, Interest, Total" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r114", "r170", "r186", "r230", "r231", "r232", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r444", "r448", "r449", "r473", "r502", "r503" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liability:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r32", "r114", "r186", "r473", "r504", "r543", "r563" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities, redeemable convertible preferred stock, and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities, redeemable convertible preferred stock and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r47", "r114", "r186", "r230", "r231", "r232", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r444", "r448", "r449", "r473", "r502", "r503", "r504" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities Fair Value Disclosure", "terseLabel": "Fair value of liability" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoanRestructuringModificationNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of loan modification, for example, but not limited to, modifications under government programs.", "label": "Loan Restructuring Modification Name [Axis]", "terseLabel": "Loan Restructuring Modification Name" } } }, "localname": "LoanRestructuringModificationNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LoanRestructuringModificationNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of loan modification, for example, but not limited to, modifications under government programs.", "label": "Loan Restructuring Modification Name [Domain]", "terseLabel": "Loan Restructuring Modification Name" } } }, "localname": "LoanRestructuringModificationNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r21", "r258", "r274", "r278", "r279", "r542", "r559" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt", "totalLabel": "Term loan and convertible notes" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Current", "terseLabel": "Current portion of long-term debt", "totalLabel": "Long-term Debt, Current Maturities, Total" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r121", "r228", "r263" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r121", "r228", "r263" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r121", "r228", "r263" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r121" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails": { "order": 0.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2021 (remaining three months)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Noncurrent", "terseLabel": "Long-term debt", "totalLabel": "Long-term Debt, Excluding Current Maturities, Total" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.", "label": "Long Term Debt Percentage Bearing Fixed Interest Rate", "terseLabel": "Accrue interest fixed rate" } } }, "localname": "LongTermDebtPercentageBearingFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r52", "r229" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r216", "r217", "r218", "r220", "r221", "r222", "r224", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r216" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss contingency accrual for potential legal losses", "periodEndLabel": "Loss Contingency Accrual, Ending Balance", "periodStartLabel": "Loss Contingency Accrual, Beginning Balance" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r216", "r219", "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss contingency damages awarded value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r216", "r219", "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss contingency damages sought value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery and Equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MandatorilyRedeemablePreferredStockMember": { "auth_ref": [ "r285", "r286" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares that an entity is required to redeem for cash or other assets at a fixed or determinable date or upon the occurrence of an event.", "label": "Mandatorily Redeemable Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "MandatorilyRedeemablePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfConvertibleNotesDerivativeLiabilitiesDeterminedUsingAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfConvertibleNotesDerivativeLiabilitiesDeterminedUsingAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfConvertibleNotesDerivativeLiabilitiesDeterminedUsingAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 }, "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 0.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds At Carrying Value", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfCashAndCashEquivalentsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash Flows From Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash Flows From Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r97", "r99", "r102" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash Flows From Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r75", "r76", "r79", "r82", "r102", "r114", "r126", "r128", "r129", "r130", "r131", "r133", "r134", "r139", "r166", "r168", "r171", "r174", "r176", "r186", "r230", "r231", "r232", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r457", "r473", "r549", "r569" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss attributable to common stockholders", "negatedLabel": "Net Loss", "terseLabel": "Net loss", "totalLabel": "Net Loss", "verboseLabel": "Net Income (Loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": { "auth_ref": [ "r105", "r106", "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Or Part Noncash Acquisition Value Of Assets Acquired1", "terseLabel": "Fair value of net assets acquired in business combination", "totalLabel": "Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesNoncurrent": { "auth_ref": [ "r53", "r118", "r496" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).", "label": "Notes Payable, Related Parties, Noncurrent", "terseLabel": "Convertible notes payable to related parties" } } }, "localname": "NotesPayableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OpenOptionContractsWrittenExpirationDates": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of the open option contracts written on the investment, in YYYY-MM-DD format.", "label": "Open Option Contracts Written Expiration Dates", "terseLabel": "Expiration date" } } }, "localname": "OpenOptionContractsWrittenExpirationDates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r166", "r168", "r171", "r174", "r176" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r489", "r491" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases Future Minimum Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r489", "r491" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": { "order": 0.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due Current", "terseLabel": "2021 (remaining three months)" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r489", "r491" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Three Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r489", "r491" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases Future Minimum Payments Due In Two Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r490" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases Rent Expense Net", "terseLabel": "Rent expense", "totalLabel": "Operating Leases, Rent Expense, Net, Total" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r546", "r566" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other.", "label": "Other Accrued Liabilities Current And Noncurrent", "terseLabel": "Others" } } }, "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r61", "r504" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Income (Expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income Expense Net", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentInKindPIKNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.", "label": "Payment In Kind P I K Note [Member]", "terseLabel": "Payment in Kind (PIK) Note" } } }, "localname": "PaymentInKindPIKNoteMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfLoanCosts": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow.", "label": "Payments Of Loan Costs", "terseLabel": "Payments of loan costs" } } }, "localname": "PaymentsOfLoanCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "auth_ref": [ "r90" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments To Acquire Business Two Net Of Cash Acquired", "negatedLabel": "Cash paid for business combination" } } }, "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r89" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchase of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r24", "r310" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred Stock Conversion Basis", "terseLabel": "Preferred stock, conversion basis, description" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price", "terseLabel": "Price per share of redeemable convertible preferred stock" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r24", "r291" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r37", "r38" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r9", "r191", "r192" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r7", "r9", "r190", "r192" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrincipalForgivenessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan modification for a reduction in the amount of unpaid principal on a loan.", "label": "Principal Forgiveness [Member]", "terseLabel": "Principal Forgiveness" } } }, "localname": "PrincipalForgivenessMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrincipalTransactionsRevenue": { "auth_ref": [ "r538" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) resulting from the difference between acquisition price and selling price or fair value of trading assets and trading liabilities, and from the firm's direct investment activity, conducted separately from customer trading activities, including, but not limited to, investments in private equity, alternative investment products, real estate, and exchanges and memberships.", "label": "Principal Transactions Revenue", "terseLabel": "revenue and net loss", "totalLabel": "Principal Transactions Revenue, Net, Total" } } }, "localname": "PrincipalTransactionsRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Gross proceeds from offering" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Net proceeds after deducting underwriting discounts and commissions", "verboseLabel": "Net proceeds from initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r91" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from long term debt", "totalLabel": "Proceeds from Issuance of Long-term Debt, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet": { "auth_ref": [ "r92" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with security instrument that either represents a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes proceeds from (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).", "label": "Proceeds From Issuance Of Long Term Debt And Capital Securities Net", "terseLabel": "Proceeds from issuance of convertible notes and borrowing under term loans, net of payment of lender fees and costs", "totalLabel": "Proceeds from Issuance of Long-term Debt and Capital Securities, Net, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfSecuredDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt wholly or partially secured by collateral. Excludes tax exempt secured debt.", "label": "Proceeds From Repayments Of Secured Debt", "terseLabel": "Proceeds from repayments of debt" } } }, "localname": "ProceedsFromRepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r75", "r76", "r79", "r96", "r114", "r126", "r133", "r134", "r166", "r168", "r171", "r174", "r176", "r186", "r230", "r231", "r232", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r442", "r445", "r446", "r450", "r451", "r457", "r473", "r552" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r41", "r210" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Property and equipment, useful life, description" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r40", "r208" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r210", "r504", "r553", "r564" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r210" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r208" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Property and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase obligation", "totalLabel": "Purchase Obligation, Total" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r355", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r495", "r499" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related party transaction, manufacturing transfer agreement amount" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r495" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Related party transactions, expenses charged" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r355", "r495", "r499", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r493", "r494", "r496", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r397", "r521", "r590" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r108", "r539", "r560" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Cash And Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to balance sheets" } } }, "localname": "RestrictedCashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r3", "r14", "r108" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Current", "terseLabel": "Restricted cash, current" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r11", "r17", "r108", "r586" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash, net of current portion" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r28", "r317", "r391", "r504", "r562", "r579", "r581" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r123", "r124", "r125", "r127", "r132", "r134", "r187", "r388", "r389", "r390", "r403", "r404", "r456", "r576", "r578" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r160", "r161", "r167", "r172", "r173", "r177", "r178", "r179", "r332", "r333", "r522" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Revenues", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r335", "r343" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue From Contract With Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Anti-dilutive Securities Outstanding in Common Stock Equivalent Excluded from Computation of Diluted Weighted Average Shares Outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule Of Business Acquisitions By Acquisition [Table]", "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule Of Cash And Cash Equivalents Table [Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule Of Debt Table [Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r364", "r383", "r393" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r196", "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]", "terseLabel": "Schedule of Intangible Assets, Net" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfImpairedFinancingReceivableTable": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Schedule of the recorded investment, unpaid principal balance, associated allowance, average recorded investment, accounting policies, and interest income recognized on the accrual and cash basis for impaired financing receivables by class of financing receivable.", "label": "Schedule Of Impaired Financing Receivable [Table]", "terseLabel": "Schedule Of Impaired Financing Receivable [Table]" } } }, "localname": "ScheduleOfImpairedFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r12", "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule Of Inventory Current Table [Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]", "terseLabel": "Schedule of Contractual Maturities of Financing Obligations" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Table [Text Block]", "terseLabel": "Schedule of Purchase Price of Acquired Assets and Liabilities" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r497", "r499" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r365", "r387" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r367", "r373", "r376" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsTable", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r56", "r111", "r148", "r149", "r287", "r289", "r290", "r291", "r292", "r294", "r295", "r297", "r301", "r307", "r310", "r311", "r312", "r314", "r315", "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsTable", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.", "label": "Schedule of Subsidiary or Equity Method Investee [Table]" } } }, "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]", "terseLabel": "Schedule of Future Amortization Expense of Intangible Assets" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling And Marketing Expense", "terseLabel": "Sales and marketing", "totalLabel": "Selling and Marketing Expense, Total" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling And Marketing Expense [Member]", "terseLabel": "Sales and Marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]", "terseLabel": "Series D Preferred Stock" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used to estimate the fair value of servicing assets and servicing liabilities.", "label": "Servicing Assets And Servicing Liabilities At Fair Value Assumptions Used To Estimate Fair Value Discount Rate", "terseLabel": "Estimate fair value, discount rate" } } }, "localname": "ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Arrangements To Obtain Goods And Services [Abstract]" } } }, "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield", "verboseLabel": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum", "terseLabel": "Expected volatility maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum", "terseLabel": "Expected volatility minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Risk-free interest rate maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Risk-free interest rate minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Number of Shares Underlying Outstanding Options, Shares Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Shares exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Aggregate intrinsic value of common stock exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Number of Shares Underlying Outstanding Options, Forfeited or Cancelled", "terseLabel": "Number of Shares Underlying Outstanding Options, Forfeited or Cancelled", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Number of Shares Underlying Outstanding Options, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r369", "r387" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending balance", "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Oustanding ending balance", "periodStartLabel": "Weighted Average Exercise Price, Outstanding beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Number of Shares Underlying Outstanding Options, Vested and Expected to Vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "auth_ref": [ "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.", "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost", "terseLabel": "Incremental compensation cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options exercised", "verboseLabel": "Aggregate exercise price of exercised shares" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r379", "r392" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term", "verboseLabel": "Expected warrant life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfFairValueOfStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Shares exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years), Shares exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted Average Remaining Contractual Term (in years), Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted Average Remaining Contractual Term (in years), Vested and Expected to Vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1", "terseLabel": "Fair value of options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issued offering price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r109", "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r111", "r114", "r136", "r137", "r138", "r140", "r142", "r148", "r149", "r150", "r186", "r230", "r235", "r236", "r237", "r241", "r242", "r291", "r292", "r297", "r301", "r309", "r473", "r596" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsTable", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r59", "r77", "r78", "r79", "r123", "r124", "r125", "r127", "r132", "r134", "r147", "r187", "r309", "r317", "r388", "r389", "r390", "r403", "r404", "r456", "r475", "r476", "r477", "r478", "r479", "r480", "r576", "r577", "r578", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r123", "r124", "r125", "r147", "r522" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r58", "r262", "r309", "r310", "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Number of common stock issued upon conversion" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r24", "r25", "r309", "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares sold and issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r309", "r317", "r371" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Number of Shares Underlying Outstanding Options, Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r59", "r309", "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r24", "r25", "r309", "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Shares subject to repurchase" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r30", "r31", "r114", "r184", "r186", "r473", "r504" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r112", "r292", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r308", "r317", "r320" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubordinatedDebt": { "auth_ref": [ "r19", "r21", "r542", "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of subordinated debt (with initial maturities beyond one year or beyond the operating cycle if longer). Subordinated debt places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.", "label": "Subordinated Debt", "periodEndLabel": "Subordinated Debt, Ending Balance", "periodStartLabel": "Subordinated Debt, Beginning Balance", "terseLabel": "Convertible notes", "totalLabel": "Subordinated Debt, Total" } } }, "localname": "SubordinatedDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r481", "r506" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r481", "r506" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r481", "r506" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r481", "r506" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r505", "r508" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary or Equity Method Investee [Line Items]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental Disclosure of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r230", "r235", "r236", "r237", "r241", "r242" ], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Carrying Amount Attributable To Parent", "periodEndLabel": "Temporary Equity, Balance", "periodStartLabel": "Temporary Equity, Balance", "terseLabel": "Redeemable convertible preferred stock, $0.001 par value, 121,732,397 shares authorized as of September 30, 2021 and December 31, 2020; 12,397,838 shares issued and outstanding as of September 30, 2021 and December 31, 2020; liquidation value of $136,168 as of September 30, 2021 and December 31, 2020" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Liquidation Preference", "terseLabel": "Redeemable convertible preferred stock, liquidation value" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r13", "r288" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity Par Or Stated Value Per Share", "terseLabel": "Redeemable convertible preferred stock ,par value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Authorized", "terseLabel": "Redeemable convertible preferred stock shares, authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Issued", "terseLabel": "Redeemable convertible preferred stock shares, issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Outstanding", "periodEndLabel": "Temporary Equity, Balance, shares", "periodStartLabel": "Temporary Equity, Balance, shares", "terseLabel": "Redeemable convertible preferred stock shares, outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ToolsDiesAndMoldsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.", "label": "Tools Dies And Molds [Member]", "terseLabel": "Tools and Dies" } } }, "localname": "ToolsDiesAndMoldsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r151", "r152", "r154", "r155", "r156", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "utrs_AccrualForInventoryInTransit": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrual for inventory in transit.", "label": "Accrual For Inventory In Transit", "terseLabel": "Accrual for inventory in transit" } } }, "localname": "AccrualForInventoryInTransit", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "utrs_AccruedCommissionsCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails": { "order": 2.0, "parentTag": "utrs_AccruedCompensation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued commissions.", "label": "Accrued Commissions Current And Noncurrent", "terseLabel": "Accrued commissions" } } }, "localname": "AccruedCommissionsCurrentAndNoncurrent", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_AccruedCompensation": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued compensation.", "label": "Accrued Compensation", "totalLabel": "Total accrued compensation" } } }, "localname": "AccruedCompensation", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_AccruedContractLiability": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued contract liability.", "label": "Accrued Contract Liability", "terseLabel": "Contract liability" } } }, "localname": "AccruedContractLiability", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "utrs_AccruedDeferredRent": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued deferred rent.", "label": "Accrued Deferred Rent", "terseLabel": "Deferred rent" } } }, "localname": "AccruedDeferredRent", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "utrs_AccruedLitigation": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrual for litigation.", "label": "Accrued Litigation", "terseLabel": "Accrual for litigation" } } }, "localname": "AccruedLitigation", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "utrs_AccruedSalesAndUseTaxes": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued sales and use taxes.", "label": "Accrued Sales And Use Taxes", "terseLabel": "Accrued sales and use taxes" } } }, "localname": "AccruedSalesAndUseTaxes", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "utrs_AmendmentToTwoThousandEighteenNotesAndTwoThousandNineteenNotesAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amendment to two thousand eighteen notes and two thousand nineteen notes agreements.", "label": "Amendment to Two thousand eighteen Notes and Two thousand Nineteen Notes Agreements [Member]", "terseLabel": "Amendment" } } }, "localname": "AmendmentToTwoThousandEighteenNotesAndTwoThousandNineteenNotesAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_AmendmentToTwoThousandEighteenTwoThousandNineteenAndTwoThousandTwentyNotesAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amendment to two thousand eighteen two thousand nineteen and two thousand twenty notes agreements.", "label": "Amendment To Two Thousand Eighteen Two Thousand Nineteen And Two Thousand Twenty Notes Agreements [Member]", "terseLabel": "Amended 2018 Note Agreements, 2019 Note Agreements, and 2020 Note Agreement" } } }, "localname": "AmendmentToTwoThousandEighteenTwoThousandNineteenAndTwoThousandTwentyNotesAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_ApicalInstrumentsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Apical Instruments, Inc.", "label": "Apical Instruments Inc [Member]", "terseLabel": "Apical Instruments Inc" } } }, "localname": "ApicalInstrumentsIncMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_AresAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ares agreement.", "label": "Ares Agreement [Member]", "terseLabel": "Ares Agreement" } } }, "localname": "AresAgreementMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_AresLoanAndConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ares Loan and Convertible Notes.", "label": "Ares Loan and Convertible Notes [Member]", "terseLabel": "Ares Loan and Convertible Notes" } } }, "localname": "AresLoanAndConvertibleNotesMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "domainItemType" }, "utrs_AresTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ares term loan.", "label": "Ares term loan [Member]", "terseLabel": "Ares Term Loan" } } }, "localname": "AresTermLoanMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails" ], "xbrltype": "domainItemType" }, "utrs_BalanceSheetComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Balance sheet components.", "label": "Balance Sheet Components [Abstract]" } } }, "localname": "BalanceSheetComponentsAbstract", "nsuri": "http://minervasurgical.com/20210930", "xbrltype": "stringItemType" }, "utrs_BalanceSheetComponentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent balance sheet components.", "label": "Balance Sheet Components [Line Items]", "terseLabel": "Balance Sheet Components [Line Items]" } } }, "localname": "BalanceSheetComponentsLineItems", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "utrs_BalanceSheetComponentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the balance sheet components.", "label": "Balance Sheet Components [Table]", "terseLabel": "Balance Sheet Components [Table]" } } }, "localname": "BalanceSheetComponentsTable", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "utrs_BostonScientificCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boston Scientific Corporation.", "label": "Boston Scientific Corporation [Member]", "terseLabel": "BSC" } } }, "localname": "BostonScientificCorporationMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current assets other receivables.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Other Receivables", "terseLabel": "Other receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOtherReceivables", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "utrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNegativeGoodwill": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed negative goodwill", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Negative goodwill", "negatedLabel": "Negative goodwill", "terseLabel": "Negative goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNegativeGoodwill", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "utrs_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantyLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed warranty liability.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Warranty Liability", "negatedLabel": "Warranty liability", "terseLabel": "Warranty liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantyLiability", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "utrs_CIBCAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CIBC Agreement.", "label": "C I B C Agreement [Member]", "terseLabel": "CIBC Agreement" } } }, "localname": "CIBCAgreementMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_ChangeInFairValueOfDerivativeLiabilities": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of derivative liabilities.", "label": "Change In Fair Value Of Derivative Liabilities", "terseLabel": "Change in fair value of derivative liabilities" } } }, "localname": "ChangeInFairValueOfDerivativeLiabilities", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "utrs_ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of redeemable convertible preferred stock warrant liability", "label": "Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability", "negatedLabel": "Change in fair value of redeemable convertible preferred stock warrant liability", "negatedTerseLabel": "Add: Change in fair value of redeemable convertible preferred stock warrant liability", "terseLabel": "Add: Change in fair value of redeemable convertible preferred stock warrant liability" } } }, "localname": "ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_ChangeOfControlOfCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "If change of control of company occurs.", "label": "Change of Control of Company [Member]", "terseLabel": "If Change of Control of Company Occurs" } } }, "localname": "ChangeOfControlOfCompanyMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_ClassOfWarrantOrRightOutstandingExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right outstanding expiration date.", "label": "Class Of Warrant Or Right Outstanding Expiration Date", "terseLabel": "Expiration date" } } }, "localname": "ClassOfWarrantOrRightOutstandingExpirationDate", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails" ], "xbrltype": "gYearMonthItemType" }, "utrs_CommonStockOptionsIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock options issued and outstanding.", "label": "Common Stock Options Issued And Outstanding", "terseLabel": "Common stock options issued and outstanding" } } }, "localname": "CommonStockOptionsIssuedAndOutstanding", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "utrs_ComputerAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer and Software.", "label": "Computer And Software [Member]", "terseLabel": "Computer and Software" } } }, "localname": "ComputerAndSoftwareMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "utrs_ConcentrationOfSuppliers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for concentration of suppliers.", "label": "Concentration Of Suppliers", "terseLabel": "Concentration of suppliers" } } }, "localname": "ConcentrationOfSuppliers", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "utrs_ContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration liability member.", "label": "Contingent Consideration Liability [Member]", "terseLabel": "Contingent Consideration Liability" } } }, "localname": "ContingentConsiderationLiabilityMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueSummaryOfRedeemableConvertiblePreferredStockWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "utrs_ConversionsOfConvertibleNotesToPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversions of convertible notes to preferred stock.", "label": "Conversions Of Convertible Notes To Preferred Stock", "terseLabel": "Conversions of convertible notes to preferred stock" } } }, "localname": "ConversionsOfConvertibleNotesToPreferredStock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceParentheticalDetails" ], "xbrltype": "sharesItemType" }, "utrs_ConvertibleNotesPayables": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payables.", "label": "Convertible Notes Payables", "terseLabel": "Convertible notes (includes $62.5 million at September 30, 2021 and $46.5 million at December 31, 2020, respectively, attributable to related parties)", "totalLabel": "Convertible notes", "verboseLabel": "Convertible notes" } } }, "localname": "ConvertibleNotesPayables", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "utrs_ConvertibleNotesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible notes shares.", "label": "Convertible Notes Shares", "terseLabel": "Convertible notes" } } }, "localname": "ConvertibleNotesShares", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "utrs_DebtInstrumentAccruedInterest": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails": { "order": 3.0, "parentTag": "utrs_ConvertibleNotesPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument accrued interest.", "label": "Debt Instrument Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "DebtInstrumentAccruedInterest", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureDebtConvertibleNotesScheduleOfConvertibleNoteDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_DebtInstrumentAdvanceClosingOfTrancheAgreementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Advance, Closing of Tranche Agreement Date.", "label": "Debt Instrument Advance Closing Of Tranche Agreement Date", "terseLabel": "Debt instrument advance, closing of tranche agreement date" } } }, "localname": "DebtInstrumentAdvanceClosingOfTrancheAgreementDate", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "utrs_DebtInstrumentAdvanceClosingOfTrancheAgreementPeriodPriorToClosing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Advance, Closing of Tranche Agreement Period Prior to Closing.", "label": "Debt Instrument Advance Closing Of Tranche Agreement Period Prior To Closing", "terseLabel": "Debt instrument advance, closing of tranche agreement period prior to closing" } } }, "localname": "DebtInstrumentAdvanceClosingOfTrancheAgreementPeriodPriorToClosing", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "utrs_DebtInstrumentAdvancedAtClosingOfAgreementTrancheA": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument Advanced at Closing of Agreement Tranche A.", "label": "Debt Instrument Advanced At Closing Of Agreement Tranche A", "terseLabel": "Debt instrument advanced at closing of agreement tranche A" } } }, "localname": "DebtInstrumentAdvancedAtClosingOfAgreementTrancheA", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_DebtInstrumentAdvancedAtClosingOfAgreementTrancheB": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument Advanced at Closing of Agreement Tranche B.", "label": "Debt Instrument Advanced At Closing Of Agreement Tranche B", "terseLabel": "Debt instrument advanced at closing of agreement tranche B" } } }, "localname": "DebtInstrumentAdvancedAtClosingOfAgreementTrancheB", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_DebtInstrumentAdvancedConditionedUponAchievingMinimumAmountInNetRevenues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument Advanced Conditioned Upon Achieving Minimum Amount in Net Revenues.", "label": "Debt Instrument Advanced Conditioned Upon Achieving Minimum Amount In Net Revenues", "terseLabel": "Minimum amount conditioned upon achieving in net revenues" } } }, "localname": "DebtInstrumentAdvancedConditionedUponAchievingMinimumAmountInNetRevenues", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_DebtInstrumentExitFeeAmount": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt instrument exit fee amount.", "label": "Debt Instrument Exit Fee Amount", "terseLabel": "Add: Exit fee" } } }, "localname": "DebtInstrumentExitFeeAmount", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanScheduleOfDebtDetails" ], "xbrltype": "monetaryItemType" }, "utrs_DebtInstrumentExtendedMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument extended maturity period.", "label": "Debt Instrument Extended Maturity Period", "terseLabel": "Debt instrument extended maturity period" } } }, "localname": "DebtInstrumentExtendedMaturityPeriod", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "utrs_DebtInstrumentFixedExitFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument fixed exit fee percentage.", "label": "Debt Instrument Fixed Exit Fee Percentage", "terseLabel": "Debt instrument fixed exit fee percentage" } } }, "localname": "DebtInstrumentFixedExitFeePercentage", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_DebtInstrumentInterestRateIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest rate increase.", "label": "Debt Instrument Interest Rate Increase", "terseLabel": "Debt instrument interest rate increase" } } }, "localname": "DebtInstrumentInterestRateIncrease", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_DebtInstrumentsAccruedInterestRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instruments Accrued Interest Rate Percentage.", "label": "Debt Instruments Accrued Interest Rate Percentage", "terseLabel": "Debt instruments accrued interest rate percentage" } } }, "localname": "DebtInstrumentsAccruedInterestRatePercentage", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_DeferredOfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferred offering costs.", "label": "Deferred Offering Costs Policy [Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "DeferredOfferingCostsPolicyTextBlock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "utrs_DeferredPaymentObligationsAdditionalAmountToBeDrawnRetained": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred payment obligations additional amount to be drawn retained.", "label": "Deferred Payment Obligations Additional Amount to be Drawn Retained", "terseLabel": "Deferred payment obligations additional amount to be drawn retained" } } }, "localname": "DeferredPaymentObligationsAdditionalAmountToBeDrawnRetained", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_DelayedCashPurchaseConsideration": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Delayed cash purchase consideration.", "label": "Delayed Cash Purchase Consideration", "terseLabel": "Delayed cash purchase consideration", "verboseLabel": "Delayed cash purchase obligation" } } }, "localname": "DelayedCashPurchaseConsideration", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "utrs_DerivativeLiabilityRelatedToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative liability related to related parties.", "label": "Derivative Liability Related To Related Parties", "terseLabel": "Derivative liabilties related to related parties" } } }, "localname": "DerivativeLiabilityRelatedToRelatedParties", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "utrs_DevelopedTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developed technology.", "label": "Developed Technology [Member]", "terseLabel": "Developed Technology" } } }, "localname": "DevelopedTechnologyMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "domainItemType" }, "utrs_DevelopmentMilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Development milestone payment.", "label": "Development Milestone Payment", "terseLabel": "Development milestone payment" } } }, "localname": "DevelopmentMilestonePayment", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_EquipmentUnderCustomerUsageAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment under customer usage agreements.", "label": "Equipment Under Customer Usage Agreements [Member]", "terseLabel": "Equipment Under Customer Usage Agreements" } } }, "localname": "EquipmentUnderCustomerUsageAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "utrs_EstimatedOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated offering costs.", "label": "Estimated Offering Costs", "terseLabel": "Estimated offering costs" } } }, "localname": "EstimatedOfferingCosts", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_EstimatedTimeToExitFromMandatoryPrepaymentDerivativeLiability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated time to exit from mandatory prepayment derivative liability.", "label": "Estimated Time To Exit From Mandatory Prepayment Derivative Liability", "terseLabel": "Estimated time to exit from mandatory prepayment derivative liability" } } }, "localname": "EstimatedTimeToExitFromMandatoryPrepaymentDerivativeLiability", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "utrs_FairValueDerivativeLiabilitiesExpectedExitDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value derivative liabilities expected exit date.", "label": "Fair Value Derivative Liabilities Expected Exit Date", "terseLabel": "Expected exit date" } } }, "localname": "FairValueDerivativeLiabilitiesExpectedExitDate", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfConvertibleNotesDerivativeLiabilitiesDeterminedUsingAssumptionsDetails" ], "xbrltype": "dateItemType" }, "utrs_FairValueOfContingentConsiderationInConnectionToBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration in connection to business combination.", "label": "Fair Value Of Contingent Consideration In Connection To Business Combination", "terseLabel": "Fair value of contingent consideration in connection to business combination" } } }, "localname": "FairValueOfContingentConsiderationInConnectionToBusinessCombination", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_FairValueOfDelayedCashConsiderationInConnectionToBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of delayed cash consideration in connection to business combination.", "label": "Fair Value Of Delayed Cash Consideration In Connection To Business Combination", "terseLabel": "Fair value of delayed cash consideration in connection to business combination" } } }, "localname": "FairValueOfDelayedCashConsiderationInConnectionToBusinessCombination", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_FiniteLivedDevelopedTechnologyGross": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Developed technology.", "label": "Finite Lived Developed Technology Gross", "terseLabel": "Developed technology" } } }, "localname": "FiniteLivedDevelopedTechnologyGross", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfIntangibleAssetNetDetails" ], "xbrltype": "monetaryItemType" }, "utrs_FiniteLivedFutureAmortizationOfIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite lived future amortization of intangible assets net.", "label": "Finite Lived Future Amortization of Intangible Assets Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedFutureAmortizationOfIntangibleAssetsNet", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "utrs_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails": { "order": 5.0, "parentTag": "utrs_FiniteLivedFutureAmortizationOfIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite lived intangible asset, expected amortization, after year four.", "label": "Finite Lived Intangible Asset Expected Amortization After Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "utrs_ForgivenessOfPPPLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Forgiveness of PPP loan.", "label": "Forgiveness Of P P P Loan", "terseLabel": "Forgiveness of PPP loan" } } }, "localname": "ForgivenessOfPPPLoan", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_GainLossOnBargainPurchase": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain Loss on Bargain Purchase.", "label": "Gain Loss On Bargain Purchase", "terseLabel": "Bargain purchase gain" } } }, "localname": "GainLossOnBargainPurchase", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "utrs_GainLossOnDebtModification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (loss) on debt modification.", "label": "Gain (Loss) on debt modification", "terseLabel": "Gain (loss) on debt modification" } } }, "localname": "GainLossOnDebtModification", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_GainLossOnExtinguishmentOfPayrollProtectionProgramLoan": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) on Extinguishment of Payroll Protection Program Loan.", "label": "Gain Loss On Extinguishment Of Payroll Protection Program Loan", "terseLabel": "Gain on extinguishment of PPP loan" } } }, "localname": "GainLossOnExtinguishmentOfPayrollProtectionProgramLoan", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "utrs_GainOnExtinguishmentOfPaycheckProtectionProgramLoan": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain On Extinguishment Of Paycheck Protection Program Loan.", "label": "Gain On Extinguishment Of Paycheck Protection Program Loan", "negatedLabel": "Gain on extinguishment of PPP loan" } } }, "localname": "GainOnExtinguishmentOfPaycheckProtectionProgramLoan", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_GenesysHTAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genesys HTA.", "label": "Genesys H T A [Member]", "terseLabel": "Genesys HTA" } } }, "localname": "GenesysHTAMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "utrs_GenesysHTASystemSymphionTissueRemovalSystemAndResectrTissueResectionDeviceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genesys HTA system symphion tissue removal system and resectr tissue resection device.", "label": "Genesys H T A System Symphion Tissue Removal System And Resectr Tissue Resection Device [Member]", "terseLabel": "IUH Products [Member]" } } }, "localname": "GenesysHTASystemSymphionTissueRemovalSystemAndResectrTissueResectionDeviceMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_HermesInnovationsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hermes Innovations, LLC", "label": "Hermes Innovations L L C [Member]", "terseLabel": "Hermes Innovations L L C" } } }, "localname": "HermesInnovationsLLCMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_HologicIncAndCytycSurgicalProductsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hologic, Inc. and Cytyc Surgical Products, LLC.", "label": "Hologic, Inc. and Cytyc Surgical Products, LLC Member", "terseLabel": "Hologic, Inc. and Cytyc Surgical Products, LLC" } } }, "localname": "HologicIncAndCytycSurgicalProductsLlcMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_InterestForgivenessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest forgiveness.", "label": "Interest Forgiveness [Member]", "terseLabel": "Interest Forgiveness" } } }, "localname": "InterestForgivenessMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_IntrauterineHealthProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intrauterine health products.", "label": "Intrauterine Health Products [Member]", "terseLabel": "Intrauterine Health Products" } } }, "localname": "IntrauterineHealthProductsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfPurchasePriceOfAcquiredAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "utrs_InventoryComponentMaterials": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory component materials.", "label": "Inventory Component Materials", "terseLabel": "Component materials" } } }, "localname": "InventoryComponentMaterials", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "utrs_IssuanceOfCommonStockUponEarlyExerciseOfStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock upon early exercise of stock options.", "label": "Issuance of Common Stock Upon Early Exercise of Stock Options", "terseLabel": "Issuance of common stock upon early exercise of stock options, shares" } } }, "localname": "IssuanceOfCommonStockUponEarlyExerciseOfStockOptions", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "utrs_IssuanceOfDerivativeInstrumentsRelatedToConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of derivative instruments related to convertible notes.", "label": "Issuance Of Derivative Instruments Related To Convertible Notes", "terseLabel": "Issuance of derivative instruments related to convertible notes" } } }, "localname": "IssuanceOfDerivativeInstrumentsRelatedToConvertibleNotes", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_IssuanceOfSeriesDRedeemableConvertiblePreferredStockInConnectionToBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of Series D redeemable convertible preferred stock in connection to business combination.", "label": "Issuance Of Series D Redeemable Convertible Preferred Stock In Connection To Business Combination", "terseLabel": "Issuance of Series D redeemable convertible preferred stock in connection to business combination" } } }, "localname": "IssuanceOfSeriesDRedeemableConvertiblePreferredStockInConnectionToBusinessCombination", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_LongTermDebtIncludingInterest": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long term debt including interest.", "label": "Long Term Debt Including Interest", "negatedLabel": "Less: interest" } } }, "localname": "LongTermDebtIncludingInterest", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtScheduleOfContractualMaturitiesOfFinancingObligationsDetails" ], "xbrltype": "monetaryItemType" }, "utrs_MaximumPercentageOfTotalRevenueDerivedFromSaleOfSingleUseDisposableProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of total revenue derived from sale of single-use (disposable) products.", "label": "Maximum Percentage Of Total Revenue Derived From Sale Of Single Use Disposable Products", "terseLabel": "Maximum percentage of total revenue derived from sale of single-use (disposable) products" } } }, "localname": "MaximumPercentageOfTotalRevenueDerivedFromSaleOfSingleUseDisposableProducts", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_MayAndSeptember2021AmendedAssetPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May and September 2021 amended asset purchase agreement.", "label": "May and September 2021 Amended Asset Purchase Agreement [Member]", "terseLabel": "May and September 2021 Amended Asset Purchase Agreement" } } }, "localname": "MayAndSeptember2021AmendedAssetPurchaseAgreementMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_MinervaESMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minerva ES.", "label": "Minerva E S [Member]", "terseLabel": "Minerva ES" } } }, "localname": "MinervaESMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "utrs_MinimumPercentageOfSaleExtendedWarrantiesOnCapitalEquipment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of sale extended warranties on capital equipment.", "label": "Minimum Percentage Of Sale Extended Warranties On Capital Equipment", "terseLabel": "Minimum percentage of sale extended warranties on capital equipment" } } }, "localname": "MinimumPercentageOfSaleExtendedWarrantiesOnCapitalEquipment", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_NonQualifiedFinancingOfConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non qualified financing of convertible preferred stock.", "label": "Non Qualified Financing of Convertible Preferred Stock [Member]", "terseLabel": "Non Qualified Financing of Convertible Preferred Stock" } } }, "localname": "NonQualifiedFinancingOfConvertiblePreferredStockMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_NumberOfCustomerAccountedForAccountsReceivableOrRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of customer accounted for accounts receivable or revenue", "label": "Number of Customer Accounted for Accounts Receivable or Revenue", "terseLabel": "Number of customer accounted for accounts receivable or revenue" } } }, "localname": "NumberOfCustomerAccountedForAccountsReceivableOrRevenue", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "utrs_OfferingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offering price per share.", "label": "Offering Price Per Share", "terseLabel": "Offering price per share" } } }, "localname": "OfferingPricePerShare", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "utrs_OtherAccruedPersonnelRelatedExpenses": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails": { "order": 3.0, "parentTag": "utrs_AccruedCompensation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other accrued personnel related expenses.", "label": "Other Accrued Personnel Related Expenses", "terseLabel": "Other accrued personnel related expenses" } } }, "localname": "OtherAccruedPersonnelRelatedExpenses", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other member.", "label": "Other [Member]", "terseLabel": "Other" } } }, "localname": "OtherMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "utrs_PaycheckProtectionProgramLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program loan.", "label": "Paycheck Protection Program Loan [Member]", "terseLabel": "Paycheck Protection Program Loan" } } }, "localname": "PaycheckProtectionProgramLoanMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtPaycheckProtectionProgramAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_PaymentOfSuccessFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of success fee.", "label": "Payment Of Success Fee", "terseLabel": "Payment of success fee" } } }, "localname": "PaymentOfSuccessFee", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_PercentageHoldingOfOutstandingPrincipalAmountByMajorityInvestorsWithOptionToConvertToPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage holding of outstanding principal amount by majority investors with option to convert to preferred stock shares.", "label": "Percentage Holding of Outstanding Principal Amount by Majority Investors with Option to Convert to preferred Stock shares", "terseLabel": "Percentage holding of outstanding principal amount by majority investors with option to convert to preferred stock shares" } } }, "localname": "PercentageHoldingOfOutstandingPrincipalAmountByMajorityInvestorsWithOptionToConvertToPreferredStockShares", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_PercentageOfInterestOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of interest owned.", "label": "Percentage of Interest Owned", "terseLabel": "Percentage of interest owned" } } }, "localname": "PercentageOfInterestOwned", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Revenue From Contract With Customer Excluding Assessed Tax.", "label": "Percentage Of Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Disaggregation of revenue" } } }, "localname": "PercentageOfRevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "percentItemType" }, "utrs_PercentageOfRevenueSubjectToPointInTimeRecognition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue subject to point-in-time recognition.", "label": "Percentage Of Revenue Subject To Point In Time Recognition", "terseLabel": "Percentage of revenue subject to point-in-time recognition" } } }, "localname": "PercentageOfRevenueSubjectToPointInTimeRecognition", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_PercentagePremiumOfOutstandingPrincipalAmountToBePrepaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage premium of outstanding principal amount to be prepaid.", "label": "Percentage Premium of Outstanding Principal Amount to be Prepaid", "terseLabel": "Percentage premium of outstanding principal amount to be prepaid" } } }, "localname": "PercentagePremiumOfOutstandingPrincipalAmountToBePrepaid", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_PreferredStockConvertibleConversionPercentagePaidByOtherPurchasers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock convertible conversion percentage paid by other purchasers.", "label": "Preferred stock Convertible Conversion Percentage Paid by Other Purchasers", "terseLabel": "Preferred stock convertible, conversion percentage paid by other purchasers." } } }, "localname": "PreferredStockConvertibleConversionPercentagePaidByOtherPurchasers", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_PrepaymentPremiumEarnedPercentageOnPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment premium earned percentage on principal.", "label": "Prepayment Premium Earned Percentage On Principal", "terseLabel": "Prepayment premium earned percentage on principal" } } }, "localname": "PrepaymentPremiumEarnedPercentageOnPrincipal", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_PrepaymentPremiumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepayment premium percentage.", "label": "Prepayment Premium Percentage", "terseLabel": "Prepayment premium percentage" } } }, "localname": "PrepaymentPremiumPercentage", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_ProceedsFromIssuanceInitialPublicOfferingGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance initial public offering gross.", "label": "Proceeds From Issuance Initial Public Offering Gross", "terseLabel": "Aggregate gross proceeds", "verboseLabel": "Gross proceeds from offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOfferingGross", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFormationAndBusinessOfCompanyAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchases Of Property And Equipment Included In Accounts Payable.", "label": "Purchases Of Property And Equipment Included In Accounts Payable", "terseLabel": "Purchases of property and equipment included in accounts payable" } } }, "localname": "PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_QualifiedFinancingOfConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Qualified financing of convertible preferred stock.", "label": "Qualified Financing of Convertible Preferred Stock [Member]", "terseLabel": "Qualified Financing of Convertible Preferred Stock" } } }, "localname": "QualifiedFinancingOfConvertiblePreferredStockMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_ReclassificationOfInventoryToPropertyAndEquipmentForCustomerUsageAgreements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of inventory to property and equipment for customer usage agreements", "label": "Reclassification Of Inventory To Property And Equipment For Customer Usage Agreements", "terseLabel": "Reclassification of inventory to property and equipment for customer usage agreements" } } }, "localname": "ReclassificationOfInventoryToPropertyAndEquipmentForCustomerUsageAgreements", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_RedeemableConvertiblePreferredStockWarrantLiability": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock warrant liability.", "label": "Redeemable Convertible Preferred Stock Warrant Liability", "terseLabel": "Redeemable convertible preferred stock warrant liability" } } }, "localname": "RedeemableConvertiblePreferredStockWarrantLiability", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "utrs_RedeemableConvertiblePreferredStockWarrantLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock warrant liability, Noncurrent.", "label": "Redeemable Convertible Preferred Stock Warrant Liability Noncurrent", "terseLabel": "Redeemable convertible preferred stock warrant liability" } } }, "localname": "RedeemableConvertiblePreferredStockWarrantLiabilityNoncurrent", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "utrs_RedeemableConvertiblePreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock warrants.", "label": "Redeemable Convertible Preferred Stock Warrants [Member]", "terseLabel": "Redeemable Convertible Preferred Stock Warrants" } } }, "localname": "RedeemableConvertiblePreferredStockWarrantsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom" ], "xbrltype": "domainItemType" }, "utrs_RedeemableConvertiblePreferredStockWarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock warrants.", "label": "Redeemable Convertible Preferred Stock Warrants [Text Block]", "terseLabel": "Redeemable Convertible Preferred Stock Warrants" } } }, "localname": "RedeemableConvertiblePreferredStockWarrantsTextBlock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrants" ], "xbrltype": "textBlockItemType" }, "utrs_RelatedPartyTransactionFeesChargedTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction Fees Charged Transactions With Related Party.", "label": "Related Party Transaction Fees Charged Transactions With Related Party", "terseLabel": "Fees charged" } } }, "localname": "RelatedPartyTransactionFeesChargedTransactionsWithRelatedParty", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_RepaymentLoanPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repayment loan percentage.", "label": "Repayment Loan Percentage", "terseLabel": "Repayment loan percentage" } } }, "localname": "RepaymentLoanPercentage", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtAresTermLoanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_RepaymentOfLoanFixedRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repayment of loan fixed rate percentage.", "label": "Repayment Of Loan Fixed Rate Percentage", "terseLabel": "Repayment of loan fixed rate percentage" } } }, "localname": "RepaymentOfLoanFixedRatePercentage", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "utrs_RepurchaseOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repurchase of common stock.", "label": "Repurchase Of Common Stock", "terseLabel": "Repurchase of common stock" } } }, "localname": "RepurchaseOfCommonStock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "utrs_ReverseStockSplitPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reverse stock split.", "label": "Reverse Stock Split Policy [Text Block]", "terseLabel": "Reverse Stock Split" } } }, "localname": "ReverseStockSplitPolicyTextBlock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "utrs_ScheduleOfAccruedCompensationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued compensation.", "label": "Schedule Of Accrued Compensation Table [Text Block]", "terseLabel": "Schedule of Accrued Compensation" } } }, "localname": "ScheduleOfAccruedCompensationTableTextBlock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "utrs_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prepaid expenses and other current assets.", "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "utrs_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of shares reserved for future issuance.", "label": "Schedule Of Shares Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of Shares Reserved for Future Issuance" } } }, "localname": "ScheduleOfSharesReservedForFutureIssuanceTableTextBlock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "utrs_SecondLienLoanAndSecurityAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Lien Loan and Security Agreements.", "label": "Second Lien Loan And Security Agreements [Member]", "terseLabel": "Second Lien Loan and Security Agreements" } } }, "localname": "SecondLienLoanAndSecurityAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_September92021AssetPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 9, 2021 asset purchase agreement.", "label": "September 9, 2021 Asset Purchase Agreement [Member]", "terseLabel": "September 9, 2021 Asset Purchase Agreement" } } }, "localname": "September92021AssetPurchaseAgreementMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_SeriesARedeemableConvertiblePreferredStockOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series a redeemable convertible preferred stock outstanding.", "label": "Series A Redeemable Convertible Preferred Stock Outstanding [Member]", "terseLabel": "Series A Redeemable Convertible Preferred Stock Outstanding" } } }, "localname": "SeriesARedeemableConvertiblePreferredStockOutstandingMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "utrs_SeriesBRedeemableConvertiblePreferredStockOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series b redeemable convertible preferred stock outstanding.", "label": "Series B Redeemable Convertible Preferred Stock Outstanding [Member]", "terseLabel": "Series B Redeemable Convertible Preferred Stock Outstanding" } } }, "localname": "SeriesBRedeemableConvertiblePreferredStockOutstandingMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "utrs_SeriesCRedeemableConvertiblePreferredStockOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series c redeemable convertible preferred stock outstanding.", "label": "Series C Redeemable Convertible Preferred Stock Outstanding [Member]", "terseLabel": "Series C Redeemable Convertible Preferred Stock Outstanding" } } }, "localname": "SeriesCRedeemableConvertiblePreferredStockOutstandingMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "utrs_SeriesDRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D redeemable convertible preferred stock.", "label": "Series D Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series D Redeemable Convertible Preferred Stock" } } }, "localname": "SeriesDRedeemableConvertiblePreferredStockMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_SeriesDRedeemableConvertiblePreferredStockOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series d redeemable convertible preferred stock outstanding.", "label": "Series D Redeemable Convertible Preferred Stock Outstanding [Member]", "terseLabel": "Series D Redeemable Convertible Preferred Stock Outstanding" } } }, "localname": "SeriesDRedeemableConvertiblePreferredStockOutstandingMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "utrs_SeriesDRedeemableConvertiblePreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D redeemable convertible preferred stock warrants.", "label": "Series D Redeemable Convertible Preferred Stock Warrants [Member]", "terseLabel": "Series D Redeemable Convertible Preferred Stock Warrants" } } }, "localname": "SeriesDRedeemableConvertiblePreferredStockWarrantsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsSummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsTable" ], "xbrltype": "domainItemType" }, "utrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement By share based payment award number of shares available for grant authorized.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Authorized", "terseLabel": "Number of Shares Available for Grant, Options authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "utrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant exercised.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised", "terseLabel": "Number of Shares Available for Grant, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "utrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedAndCancelled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant forfeited and cancelled.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited And Cancelled", "negatedLabel": "Number of Shares Available for Grant, Options forfeited or cancelled", "negatedTotalLabel": "Number of Shares Available for Grant, Options forfeited or cancelled", "terseLabel": "Number of Shares Available for Grant, Options forfeited or cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedAndCancelled", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "utrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant granted.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted", "negatedLabel": "Number of Shares Available for Grant, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "utrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Number", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Number", "periodEndLabel": "Number of Shares Available for Grant, Outstanding Ending balance", "periodStartLabel": "Number of Shares Available for Grant, Outstanding Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantNumber", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "utrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options authorized.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Authorized", "terseLabel": "Number of Shares Underlying Outstanding Options, Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "utrs_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAggregateExercisePricesOfEarlyExercisedShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award options aggregate exercise prices of early exercised shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Aggregate Exercise Prices Of Early Exercised Shares", "terseLabel": "Aggregate exercise prices of early exercised shares" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAggregateExercisePricesOfEarlyExercisedShares", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "utrs_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period, value, vesting of early exercised stock options.", "label": "Stock Issued During Period Value Vesting Of Early Exercised Stock Options", "terseLabel": "Vesting of early exercised stock options" } } }, "localname": "StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "utrs_SummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "summary of the outstanding redeemable convertible preferred stock warrants.", "label": "Summary Of Outstanding Redeemable Convertible Preferred Stock Warrants Table [Text Block]", "terseLabel": "Summary of Outstanding Redeemable Convertible Preferred Stock Warrants" } } }, "localname": "SummaryOfOutstandingRedeemableConvertiblePreferredStockWarrantsTableTextBlock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsTable" ], "xbrltype": "textBlockItemType" }, "utrs_SymphionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Symphion member.", "label": "Symphion [Member]", "terseLabel": "Symphion" } } }, "localname": "SymphionMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRevenueScheduleOfDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "utrs_TemporaryEquityStockIssuanceOfSeriesDRedeemableConvertiblePreferredStockUnderBusinessCombinationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity, Stock issuance of series D redeemable convertible preferred stock under business combination, shares.", "label": "Temporary Equity Stock Issuance Of Series D Redeemable Convertible Preferred Stock Under Business Combination Shares", "terseLabel": "Issuance of Series D redeemable convertible preferred stock in connection with business combination, shares" } } }, "localname": "TemporaryEquityStockIssuanceOfSeriesDRedeemableConvertiblePreferredStockUnderBusinessCombinationShares", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "utrs_TemporaryEquityStockIssuanceOfSeriesDRedeemableConvertiblePreferredStockUnderBusinessCombinationValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity, Stock issuance of series D redeemable convertible preferred stock under business combination, value.", "label": "Temporary Equity Stock Issuance Of Series D Redeemable Convertible Preferred Stock Under Business Combination Value", "terseLabel": "Issuance of Series D redeemable convertible preferred stock in connection with business combination" } } }, "localname": "TemporaryEquityStockIssuanceOfSeriesDRedeemableConvertiblePreferredStockUnderBusinessCombinationValue", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "utrs_TwoThousandEighteenAndTwoThousandNineteenNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Eighteen and Two Thousand Nineteen Notes.", "label": "Two Thousand Eighteen and Two Thousand Nineteen Notes [Member]", "terseLabel": "2018 and 2019 Notes" } } }, "localname": "TwoThousandEighteenAndTwoThousandNineteenNotesMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_TwoThousandEighteenNoteAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 note agreements.", "label": "Two Thousand Eighteen Note Agreements [Member]", "terseLabel": "2018 Note Agreements" } } }, "localname": "TwoThousandEighteenNoteAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_TwoThousandEighteenSecondLienLoanAndSecurityAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen second lien loan and security agreements.", "label": "Two Thousand Eighteen Second Lien Loan and Security Agreements [Member]", "terseLabel": "2018 Note Agreements" } } }, "localname": "TwoThousandEighteenSecondLienLoanAndSecurityAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_TwoThousandEighteenTwoThousandNineteenAndTwoThousandTwentyNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Eighteen Two Thousand Nineteen and Two Thousand Twenty Notes.", "label": "Two Thousand Eighteen Two Thousand Nineteen and Two Thousand Twenty Notes [Member]", "terseLabel": "Notes" } } }, "localname": "TwoThousandEighteenTwoThousandNineteenAndTwoThousandTwentyNotesMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_TwoThousandNineteenNoteAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 note agreements.", "label": "Two Thousand Nineteen Note Agreements [Member]", "terseLabel": "2019 Note Agreements" } } }, "localname": "TwoThousandNineteenNoteAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_TwoThousandNineteenSecondLienLoanAndSecurityAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen second lien loan and security agreements.", "label": "Two thousand Nineteen second lien loan and security agreements [Member]", "terseLabel": "2019 Note Agreements" } } }, "localname": "TwoThousandNineteenSecondLienLoanAndSecurityAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_TwoThousandTwentyNoteAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Note Agreements.", "label": "Two Thousand Twenty Note Agreements [Member]", "terseLabel": "2020 Note Agreements" } } }, "localname": "TwoThousandTwentyNoteAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_TwoThousandTwentySecondLienLoanAndSecurityAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty second lien loan and security agreements.", "label": "Two thousand twenty second lien loan and security agreements [Member]", "terseLabel": "2020 Note Agreement" } } }, "localname": "TwoThousandTwentySecondLienLoanAndSecurityAgreementsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_UnauditedInterimFinancialInformationPolicy": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for unaudited interim financial information.", "label": "Unaudited Interim Financial Information Policy", "terseLabel": "Unaudited interim financial information" } } }, "localname": "UnauditedInterimFinancialInformationPolicy", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "utrs_UnvestedEarlyExercisedCommonStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested early exercised common stock options.", "label": "Unvested Early Exercised Common Stock Options [Member]", "terseLabel": "Unvested Early Exercised Common Stock Options" } } }, "localname": "UnvestedEarlyExercisedCommonStockOptionsMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesOutstandingInCommonStockEquivalentExcludedFromCom" ], "xbrltype": "domainItemType" }, "utrs_VestingOfEarlyExercisedStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Vesting of early exercised stock options.", "label": "Vesting Of Early Exercised Stock Options", "terseLabel": "Vesting of early exercised stock options" } } }, "localname": "VestingOfEarlyExercisedStockOptions", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "utrs_VoluntarilyConvertIntoSharesOfPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voluntarily convert into shares of preferred stock.", "label": "Voluntarily Convert into Shares of Preferred Stock [Member]", "terseLabel": "Voluntarily Convert into Shares of Preferred Stock" } } }, "localname": "VoluntarilyConvertIntoSharesOfPreferredStockMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureDebtConvertibleNotesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "utrs_WarrantsForSeriesDRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants for Series D redeemable convertible preferred stock.", "label": "Warrants For Series D Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Warrants For Series D Redeemable Convertible Preferred Stock" } } }, "localname": "WarrantsForSeriesDRedeemableConvertiblePreferredStockMember", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockWarrantsScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "utrs_WarrantsToPurchaseRedeemableConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase redeemable convertible referred stock.", "label": "Warrants To Purchase Redeemable Convertible Preferred Stock", "terseLabel": "Warrants to purchase redeemable convertible preferred stock" } } }, "localname": "WarrantsToPurchaseRedeemableConvertiblePreferredStock", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/Role_DisclosureStockholdersDeficitScheduleOfSharesReservedForFutureIssuanceDetails" ], "xbrltype": "sharesItemType" }, "utrs_WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average shares used in computing net loss per share basic and diluted", "label": "Weighted-average Shares Used in Computing Net Loss Per Share Basic and Diluted", "terseLabel": "Weighted-average shares used in computing net loss per share, basic and diluted", "verboseLabel": "Weighted-average common stock outstanding" } } }, "localname": "WeightedAverageSharesUsedInComputingNetLossPerShareBasicAndDiluted", "nsuri": "http://minervasurgical.com/20210930", "presentation": [ "http://minervasurgical.com/20210930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails", "http://minervasurgical.com/20210930/taxonomy/role/Role_StatementCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22026-110879" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130534-203044" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r396": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6387-128476" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6393-128476" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6396-128476" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6527-128477" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6571-128477" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(f)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r468": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r508": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(d)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122596-111746" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=35711157&loc=d3e42567-110969" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.8)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column F))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r591": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r592": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r593": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r594": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r595": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r596": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r597": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r598": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r599": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" } }, "version": "2.1" }